Phase I Study of SB-480848 (Darapladib) -A Double Blind, Randomised, Placebo-Controlled, Parallel-Group, Repeat Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SB-480848 in Healthy Japanese Male Subjects
Phase of Trial: Phase I
Latest Information Update: 01 Jun 2012
At a glance
- Drugs Darapladib (Primary)
- Indications Atherosclerosis
- Focus Adverse reactions; Pharmacokinetics
- Sponsors GlaxoSmithKline
- 10 Jun 2017 Biomarkers information updated
- 12 Oct 2008 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 11 Mar 2008 New trial record.